Evidence map›Paper›PMID 38299149›Full record

ArticleFrontiers in immunology2023

People who use drugs show no increase in pre-existing T-cell cross-reactivity toward SARS-CoV-2 but develop a normal polyfunctional T-cell response after standard mRNA vaccination.

Murat Gainullin, Lorenzo Federico, Julie Røkke Osen, Viktoriia Chaban, Hassen Kared, Amin Alirezaylavasani, Fridtjof Lund-Johansen, Gull Wildendahl, Jon-Aksel Jacobsen, Hina Sarwar Anjum and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Murat Gainullin *KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Lorenzo Federico *KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Julie Røkke OsenKG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Viktoriia ChabanKG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Hassen KaredKG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Amin AlirezaylavasaniKG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Fridtjof Lund-JohansenDepartment of Immunology, Oslo University Hospital, Oslo, Norway.
Gull WildendahlAgency for Social and Welfare Services, Oslo, Norway.
Jon-Aksel JacobsenAgency for Social and Welfare Services, Oslo, Norway.
Hina Sarwar AnjumAgency for Social and Welfare Services, Oslo, Norway.
Richard StratfordNEC OncoImmunity AS, Oslo, Norway.
Simen TennøeNEC OncoImmunity AS, Oslo, Norway.
Brandon MaloneNEC OncoImmunity AS, Oslo, Norway.
Trevor ClancyNEC OncoImmunity AS, Oslo, Norway.
John T VaageDepartment of Immunology, Oslo University Hospital, Oslo, Norway.
Kathleen HenriksenAgency for Social and Welfare Services, Oslo, Norway.
Linda Wüsthoff *Unit for Clinical Research on Addictions, Oslo University Hospital, Oslo, Norway.
Ludvig A Munthe *KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
University of Oslo · NOOslo University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

People who use drugs (PWUD) are at a high risk of contracting and developing severe coronavirus disease 2019 (COVID-19) and other infectious diseases due to their lifestyle, comorbidities, and the detrimental effects of opioids on cellular immunity. However, there is limited research on vaccine responses in PWUD, particularly regarding the role that T cells play in the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we show that before vaccination, PWUD did not exhibit an increased frequency of preexisting cross-reactive T cells to SARS-CoV-2 and that, despite the inhibitory effects that opioids have on T-cell immunity, standard vaccination can elicit robust polyfunctional CD4

Indexed as

Communicable DiseasesCOVID-19Analgesics, OpioidHumansRNA, MessengerSARS-CoV-2VaccinationAnalgesics, OpioidRNA, Messengerantiviral immunityopioids and immune responsespeople who use drugsSARS-CoV-2 vaccinationT cell functionalityT cell responsesT cell subsets

Identifiers

PMID38299149
PMCPMC10827924
OpenAlexW4390953788

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.